|
Multiple manufacturers are expected to launch generic versions of Takeda's Vyvanse in the next week. Vyvanse (lisdexamfetamine dimesylate) is the #1-prescribed ADHD medication in the nation, with $4.6 billion in annual U.S. sales.
The timing of the generic releases is critical and demand is expected to be very high for lower-cost generic products as millions of children head back to school amid an ongoing shortage of Adderall.
At least three suppliers are expected to launch products by Aug. 25 or sooner. Teva, Amneal, Novartis’ Sandoz and Viatris all have received FDA generic approvals for the drug.
All capsule strengths are expected to be available, though releases may be staggered by supplier. A high rate of conversion to the generic capsules is expected, and prices may drop as more suppliers enter the market. A chew-tab option may also launch Aug. 25 (suppliers unknown).
Considerations for Planning & Ordering
- For each product strength, evaluate your current Vyvanse inventory, expected refills, and historical brand usage before placing any additional orders.
- Use RxCompass to evaluate dispensing by product strength:
-
RxCompass Top NDC report (Transactional Reports > Dispensing)
Use a year-to-date timeframe looking at Top “25000” to capture all dispensing.
Once the report loads, sort by the Drug Name column then use the search function to quickly locate Vyvanse
- Click the blue Rx Count hyperlink to view reimbursement and gross profit by claim
Reminder #1: RxCompass users can access a workflow called Inquiry & Research to efficiently evaluate reimbursement performance by NDC, plan and patient/household as needed. Please contact your American Pharmacies representative for guidance on this recommended workflow. A useful instructional guide is available in RxCompass under Help > Training Resources.
Reminder #2: Some commercial plans have brand (BER) and generic (GER) rates, which could affect net profitability. Contact the Elevate Help Desk for further information:
Hours: M-F, 8 am - 7 pm CST
Phone: (888) 880-1388
Email: elevate@amerisourcebergen.com
| 
